Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463027 | 0.83 | BRAF (0.49) | BRAFCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL9930708 | 0.79 | BRAF (0.73) | BRAFCYP2C9 | |
| SCHEMBL1492014 | 0.79 | BRAF (0.50) | BRAFCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9930469 | 0.78 | BRAF (0.46) | BRAF | |
| SCHEMBL9930354 | 0.78 | BRAF (0.49) | BRAFCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1461792 | 0.76 | AURKA (0.53) | BRAFCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9930862 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL9930740 | 0.75 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL1461840 | 0.75 | BRAF (0.53) | BRAFCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9930889 | 0.75 | KDR (0.35) | BRAFCYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885CYP1A2 2189/4885CYP3A4 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.